Orgalutran 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
IB/0055 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
24/03/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
N/0056 
Minor change in labelling or package leaflet not 
20/03/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/1517/
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
202202 
ganirelix 
IA/0054 
B.I.a.2.a - Changes in the manufacturing process of 
05/07/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0052 
B.I.b.2.e - Change in test procedure for AS or 
04/01/2022 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
N/0051 
Minor change in labelling or package leaflet not 
27/10/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0050 
Transfer of Marketing Authorisation 
17/03/2021 
13/04/2021 
SmPC, 
N/0049 
Minor change in labelling or package leaflet not 
18/01/2021 
13/04/2021 
connected with the SPC (Art. 61.3 Notification) 
Labelling and 
PL 
PL 
II/0046 
Update of section 4.2 of the SmPC in order to include 
14/01/2021 
13/04/2021 
SmPC, 
Section 4.2 of the SmPC was updated to inform users that 
information on handling air bubbles in the pre-filled 
Labelling and 
the bubbles are expected and removal of these is not 
syringes. The MAH aligned the Package Leaflet 
accordingly and took the opportunity to update the 
list of local representatives and to implement minor 
editorial changes in the PI. 
PL 
needed, after routine surveillance of safety and quality 
complaint data for Orgalutran 0.5 mg/ml solution for 
injection has identified the presence of air bubbles as a 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
N/0048 
Minor change in labelling or package leaflet not 
11/12/2020 
13/04/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0047/G 
This was an application for a group of variations. 
05/11/2020 
n/a 
source of customer questions. 
B.II.c.3.z - Change in source of an excipient or 
reagent with TSE risk - Other variation 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0045 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/04/2020 
13/04/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
II/0043 
Update of sections 4.4 and 4.8 of the SmPC to 
26/04/2019 
04/10/2019 
SmPC and PL 
The SmPC section 4.4 was updated to include under 
include anaphylaxis (including anaphylactic shock), 
angioedema, and urticaria under hypersensitivity 
reactions. 
In addition, the MAH took the opportunity to include 
minor editorial corrections in the SmPC and to 
update the list of local representatives (PT and NL) in 
the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
“Hypersensitivity reaction”: 
Cases of hypersensitivity reactions (both generalised and 
local), have been reported with Orgalutran, as early as with 
the first dose, during post marketing surveillance. These 
events have included anaphylaxis (including anaphylactic 
shock), angioedema and urticaria. (See section 4.8.) If a 
hypersensitivity reaction is suspected, Orgalutran should be 
discontinued and appropriate treatment administered.  
The SmPC section 4.8 was updated to include the adverse 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new quality, preclinical, clinical or pharmacovigilance 
data 
reaction anaphylaxis (including anaphylactic shock), 
angioedema and urticaria) with frequency “very rare”. 
The PL has been updated accordingly. 
IB/0044/G 
This was an application for a group of variations. 
10/04/2019 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
II/0041 
Update of sections 4.4 and 6.5 of the SmPC to clarify 
31/01/2019 
04/10/2019 
SmPC, 
Each pre filled syringe is affixed with a needle closed by a 
that this product is in contact with dry natural 
Labelling and 
needle cover. The needle cover contains dry natural 
rubber/latex, which may cause allergic reactions. The 
PL 
rubber/latex which comes into contact with the needle and 
labelling and Package Leaflet have been updated 
accordingly. In addition, the MAH took the 
opportunity to update the contact details of the local 
representative in Belgium in the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
may cause allergic reactions. 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
data 
IA/0042 
A.7 - Administrative change - Deletion of 
28/09/2018 
04/10/2019 
Annex II and 
manufacturing sites 
PL 
T/0040 
Transfer of Marketing Authorisation 
20/04/2018 
29/06/2018 
SmPC, 
Labelling and 
PL 
PSUSA/1517/
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
201702 
ganirelix 
N/0037 
Minor change in labelling or package leaflet not 
05/01/2017 
11/04/2017 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0035 
C.I.z - Changes (Safety/Efficacy) of Human and 
28/04/2016 
11/04/2017 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IA/0036/G 
This was an application for a group of variations. 
19/04/2016 
n/a 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0034/G 
This was an application for a group of variations. 
27/11/2015 
n/a 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0033 
B.II.b.2.a - Change to importer, batch release 
24/03/2015 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
N/0032 
Minor change in labelling or package leaflet not 
18/11/2014 
11/04/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0031 
B.I.b.1.z - Change in the specification parameters 
19/09/2014 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IG/0404 
A.4 - Administrative change - Change in the name 
14/02/2014 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IG/0366 
C.I.8.a - Introduction of or changes to a summary of 
08/11/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0027 
Transfer of Marketing Authorisation 
09/08/2013 
19/09/2013 
SmPC, 
N/0028 
Minor change in labelling or package leaflet not 
15/08/2013 
11/04/2017 
connected with the SPC (Art. 61.3 Notification) 
Labelling and 
PL 
PL 
II/0025 
Update of sections 4.4, 4.8 and 6.5 of the SmPC  
19/07/2012 
10/09/2012 
SmPC, Annex 
In this variation sections 4.4, 4.8 and 6.5 of the SmPC 
with safety information concerning allergic reactions 
II, Labelling 
were updated with safety information (derived from 
that may be caused by the natural rubber latex in 
and PL 
postmarketing data) concerning allergic reactions that may 
the packaging of Orgalutran. Updates of the labelling 
(section 7) and Package leaflet (sections 2, 4 and 6) 
are proposed accordingly.  
In addition updates of the Product Information 
according to the QRD template (version 8) and the 
SmPC Guideline (rev2).   
Furthermore the applicant takes the opportunity to 
update the list of local representatives (Netherlands, 
Iceland, Lithuania). 
The requested variation proposed amendments to 
the SmPC, Annex II, Labelling and Package Leaflet. 
C.I.4 - Variations related to significant modifications 
of the SPC due in particular to new quality, pre-
clinical, clinical or pharmacovigilance data 
IG/0184 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/08/2012 
n/a 
Veterinary Medicinal Products - Other variation 
N/0024 
Minor change in labelling or package leaflet not 
22/12/2011 
10/09/2012 
PL 
connected with the SPC (Art. 61.3 Notification) 
be caused by the natural rubber latex in the packaging of 
Orgalutran. The labelling (section 7) and Package leaflet 
(sections 2, 4 and 6) are updated accordingly. Especially 
the information that the needle shield is made of natural 
rubber latex is important to warn the subjects with history 
of latex allergy. It is also clarified in the SmPC that the 
rubber piston (in pre-filled syringes) does not contain latex. 
The updates of the Product Information according to the 
QRD template (version 8) and the SmPC Guideline (rev2) 
and to the list of local representatives (Netherlands, 
Iceland, Lithuania) were accepted. 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0117/G 
This was an application for a group of variations. 
18/11/2011 
18/11/2011 
Annex II 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
C.I.9.g - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the site 
undertaking pharmacovigilance activities 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
N/0022 
Minor change in labelling or package leaflet not 
26/07/2011 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0021 
A.5.b - Administrative change - Change in the name 
17/06/2011 
n/a 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
II/0019 
C.I.3.b - Implementation of change(s) requested 
16/12/2010 
27/01/2011 
SmPC, Annex 
SmPC section 4.8 of the SmPC has been updated further to 
following the assessment of an USR, class labelling, a 
II and PL 
assessment of FUM 25.  Following the assessment of 
PSUR, RMP, FUM/SO, data submitted under Article 
45/46, or amendments to reflect a Core SPC - 
Change(s) with new additional data submitted by the 
MAH 
variation II-16 (change in posology) a safety report was 
submitted (FUM25), showing a similar safety profile for 
Orgalutran, whether started on day 5 or day 6 of an 
ovarian stimulation protocol for assisted reproduction 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
11/11/2010 
n/a 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
R/0018 
Renewal of the marketing authorisation. 
18/02/2010 
10/05/2010 
SmPC, 
Based on the CHMP review of the available information and 
techniques. In addition changes to SmPC sections 4.1 ; 4.2 
; 5.1 to add reference to corifollitropin alfa (Elonva).  The 
PL was amended accordingly. 
Labelling and 
on the basis of a re-evaluation of the benefit risk balance, 
PL 
the CHMP is of the opinion that the quality, safety and 
efficacy of this medicinal product continues to be 
adequately and sufficiently demonstrated and therefore 
considered that the benefit risk profile of Orgalutran 
continues to be favourable.  
The CHMP is also of the opinion that the renewal can be 
granted with unlimited validity. 
II/0016 
Update of the section 4.2, 4.8 and 5.1 of the 
17/12/2009 
22/01/2010 
SmPC and PL 
Update of the SmPC (section 4.2) to update the start day 
Summary of Product Characteristics and section 3 of 
(day 5 or day 6) of treatment with Orgalutran for 
Package Leaflet. 
Update of Summary of Product Characteristics and 
Package Leaflet 
Controlled Ovarian Stimulation during ART, depending on 
the ovarian response. 
Consequently changes are also introduced in section 4.8 
and 5.1 of the SPC.  
The Package leaflet is amended accordingly (section 3). 
IA/0017 
IA_09_Deletion of manufacturing site 
21/08/2009 
n/a 
II/0015 
To change the manufacturing process of the active 
25/06/2009 
02/07/2009 
substance. 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change(s) to the manufacturing process for the 
active substance 
II/0014 
Update of section 4.4 "Special warnings and 
13/12/2007 
18/01/2008 
SmPC and PL 
Further to the assessment of PSUR 009, the MAH updated 
precautions for use" of the SPC further to the 
assessment of the PSUR 009 in order to include a 
sentence regarding tubal abnormalities and the risk 
of ectopic pregnancies. The PL was amended 
accordingly. 
Update of Summary of Product Characteristics and 
Package Leaflet 
section 4.4 "Special warnings and precautions for use" of 
the SPC to include the following warning on tubal 
abnormalities and the incidence of ectopic pregnancies: 
'Since infertile women undergoing assisted reproduction 
and particularly IVF, often have tubal abnormalities the 
incidence of ectopic pregnancies might be increased. Early 
Ultrasound confirmation that a pregnancy is intrauterine is 
therefore important.'  
Section 2 "Before you use Orgalutran" of the PL was 
amended accordingly. 
II/0012 
Update of section 4.4 of the Summary of Product 
26/04/2007 
04/06/2007 
SmPC, Annex 
Further to the assessment of the FUM 009 (prospective 
Characteristics (SPC) further to the Assessment of 
II, Labelling 
follow-up study on pregnancies) the MAH updated the 
the FUM 009 (prospective follow-up study on 
pregnancies) in order to include a statement on 
congenital malformations in children after Orgalutran 
treatment of their mothers. 
In addition, the Product Information has been 
updated in accordance to the QRD template version 
7.2. 
Update of Summary of Product Characteristics, 
Labelling and Package Leaflet 
and PL 
section 4.4 of the SPC in order to include the incidence of  
congenital malformations in children after Orgalutran 
treatment of their mothers in comparison with GnRH 
agonist treatment as follows: ''In clinical trials investigating 
more than 1000 newborns it has been demonstrated that 
the incidence of congenital malformations in children born 
after COH treatment using Orgalutran is comparable with 
that reported after COH treatment using GnRH agonist''.  
The Package leaflet was amended accordingly. In addition 
the Product Information updated in accordance to the latest 
version of QRD template. 
IA/0013 
IA_04_Change in name and/or address of a manuf. 
13/04/2007 
n/a 
of the active substance (no Ph. Eur. cert. avail.) 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0011 
Update of Summary of Product Characteristics and 
15/09/2005 
25/10/2005 
SmPC and PL 
Package Leaflet 
R/0010 
Renewal of the marketing authorisation. 
16/12/2004 
03/03/2005 
SmPC, Annex 
II, Labelling 
and PL 
N/0009 
Minor change in labelling or package leaflet not 
16/08/2004 
n/a 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
N/0008 
Minor change in labelling or package leaflet not 
01/07/2003 
18/07/2003 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
I/0007 
24_Change in test procedure of active substance 
28/03/2003 
02/04/2003 
I/0006 
14_Change in specifications of active substance 
28/03/2003 
02/04/2003 
II/0005 
Change(s) to container 
18/12/2002 
09/01/2003 
Replacement of  the soft needle shield by a rigid needle 
shield. 
II/0004 
Update of Summary of Product Characteristics 
17/01/2002 
18/04/2002 
SmPC 
I/0002 
20_Extension of shelf-life as foreseen at time of 
16/07/2001 
n/a 
SmPC, 
authorisation 
Labelling and 
PL 
I/0001 
24_Change in test procedure of active substance 
07/03/2001 
13/03/2001 
Page 11/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
